Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.


TSX:HLS - Post by User

Bullboard Posts
Post by Bobwinson Nov 11, 2011 12:23pm
219 Views
Post# 19230158

price action

price actionLast qtr I guessed that the price would fall pretty dramatically after the ex-dividend date and earnings report.
Price spiked to  C$2.20 but faded to 1.53 in early October.  Unfortunately it didn't say over C$2 long enough for me to sell.  I did add a few in the 1.60 range.   
This time around, we didn't get a big spike but a more gradual and hopefully sustainable level around the C$2+ mark.  
We should continue this stairstepping higher as Automodular creates more credibility with each profitable qtr.  
Also this time around the dividend is much less so there should be less of a tendency to sell immediately after receiving the dividend.  .10 is still a nice dividend but not so extraordinary like the last few.  
Volume not huge but decent number of buyers wanting shares.  I have a sub C$2 bid in case there are ex dividend sellers this time.
Bullboard Posts